Publicación:
Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis

Vista sencilla de ítem
dc.contributor.authorSantos Moreno, Pedro
dc.contributor.authorSánchez, Guillermo
dc.contributor.authorCastro, Carlos
dc.date.accessioned2022-02-21T18:46:34Z
dc.date.available2022-02-21T18:46:34Z
dc.date.issued2019-02
dc.description.abstractWe determined whether rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) can predict remission or severe disability in rheumatoid arthritis (RA) patients treated with anti-tumor necrosis factor (TNF) alpha drugs. We performed a cohort study based on the clinical data from a referral center for the treatment of RA in Bogotá, Colombia, were included patients aged ≥18 years with diagnosis of RA with an active disease and for whom a treatment scheme was begun with anti- TNF alpha medication, with a minimum follow-up time of 12 months. Disease activity of Rheumatoid Arthritis was assessed through measurement of RF, ACPA, disease activity score (DAS28), and health assessment questionnaire (HAQ). We calculated the incidence rates (IRs) for remission and severe disability. We also calculated the incidence rate ratio (IRR) for each outcome by adjusting for possible confounders using the Poisson regression method. The hypothesis was tested with a P value of <.05. Statistical analysis was performed in Stata 15. We included 400 patients receiving an anti-TNF alpha agent. Median age was 60 years, and 322 patients were women (80.5%). RF was positive in 357 patients (89%), ACPA in 348 patients (87%), and co-positivity in 324 patients (81%). Median follow-up was 41 months (range, 12–79 months). The IR for remission was 23 per 100 person-years in RF-negative patients and 16 per 100 personyears in RF-positive patients. The adjusted IRR (age sex, treatment, and ACPA) was 1.51 (95%CI, 1.05–2.18). The IR for severe disability was 10.8 per 100 person-years in the RF-positive cohort and 2.3 per 100 person-years in the RF-negative cohort. The IRR adjusted for these factors was 4.37 (95%CI, 1.6–12). Co-positivity had a similar behavior to RF. No differences were recorded in the rates of remission or disability in ACPA-positive and ACPA-negative patients. Our findings suggest that remission is less frequent and severe disability more frequent in RF-positive patients treated with anti- TNF alpha agents than in RF-negative patients. Abbreviations: ACPA = anticyclic citrullinated peptide antibody, DAS28 = disease activity score, DMARDs = disease-modifying antirheumatic drugs, HAQ = health assessment questionnaire, IR = incidence rate, IRR = incidence rate ratio, RF = rheumatoid factor, TNF = tumor necrosis factor.eng
dc.format.extent8 p.spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.urihttps://repositorio.fucsalud.edu.co/handle/001/1990
dc.language.isoengspa
dc.publisherWolters Kluwer Health, Inc.spa
dc.publisher.placeEstados Unidosspa
dc.relation.citationendpagee14188spa
dc.relation.citationissue5spa
dc.relation.citationstartpagee14181spa
dc.relation.citationvolume98spa
dc.relation.ispartofMedicine e-ISSN:0025-7974 Vol.98 N°5 (2019)
dc.relation.ispartofjournalMedicinespa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.sourcehttps://journals.lww.com/md-journal/Fulltext/2019/02010/Rheumatoid_factor_as_predictor_of_response_to.20.aspx
dc.subject.decsFactor reumatoide
dc.subject.decsArtritis reumatoide
dc.subject.decsRemisión
dc.subject.decsAnticuerpos antiproteína citrulinada
dc.subject.lembDiscapacidad
dc.subject.proposalAnti-cyclic citrullinated peptide antibodieseng
dc.subject.proposalDisabilityeng
dc.subject.proposalRemissioneng
dc.subject.proposalRheumatoid arthritiseng
dc.subject.proposalRheumatoid factoreng
dc.titleRheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritiseng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.redcolhttps://purl.org/redcol/resource_type/WPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients.pdf
Tamaño:
1.51 MB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
15.06 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos